Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 58.6%

Neg 58.6% Neu 0% Pos 0%

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $26 to $20.